. However, recent studies from this laboratory suggest that significant conversion of A-I to A-II occurs in the renal circulation (9), in the intestinal vascular bed (7), and in the vasculature supplied by the hepatic artery (6). Evidence that local formation of A-II from A-I also occurs in the hindlimb has recently been reported (2). In three dogs two rubber tourniquets were tied between the femur and thigh muscles, taking care not to damage the sciatic and femoral nerves. Virtually all flow to the hindlimb was via the perfusion pump, whereas flow draining the limb was largely through the femoral vein. The femoral vein was cannulated in the inguinal area with a T tube: one arm of the T was inserted distally, whereas the opposite arm was inserted proximally.
A short segment of rubber tubing which could be opened or closed to the atmosphere by means of a clamp was attached to the side-arm. With the clamp closed, drugs injected in the perfusion line circulated through the limb and returned to the heart. With the clamp opened and the femoral vein distal to the T tube occluded, drugs injected in the perfusion line circuited through the limb, but were diverted from the dog so that none reached the systemic circulation. Thus, the direct effects of A-I on the hindlimb vasculature could be evaluated.
During the diversion maneuver (2-3 min), blood from a donor dog was infused into a jugular vein at a rate equal to the hindlimb flow rate. The drugs used were n) A-I (Schwarz BioResearch, Inc., [AspI, Ileuj-] (6, 7, 9) . Drugs were dissolved in saline, adjusted to pH 7.3, and stored in the frozen state. In each experiment, the animal was challenged with A-I ( 1.3 lug/kg iv) and ii-11 (1.3 pg/kg iv) t o insure that agonists did not deteriorate during storage. Doses of A-I tested lrvere 02, 0.4, 0.8, 1.6, and 3.2 pg, whereas doses of A-II tested were 0.1, 0.2, 0.4, 0.8, and 1.6 pg. The maximal increase in perfusion pressure that occurred after drug injection was taken as the principle response and expressed as percent of control perfusion pressure (6). The ratio of equipotent doses of A-II to A-I, with respect to increasing hindlimb perfusion pressure multiplied by 1.25 (to correct for the difference in molecular weight between A-I and A-II), was used to calculate percent conversion of A-I to A-II (7-9). Responses to A-I and A-II in the presence and absence of SQ 20881 ( 100 pg/kg, bolus injection iv) were studied in eight dogs. To insure that inhibition of the converting enzyme with SQ 20881 had occurred, systemic pressor responses produced with A-I ( 1.3 lug/kg iv) and A-II ( 1.3
Pg/kg > iv were assessed before and 5 min after administration of SQ 20881. Systemic responses were also assessed after all challenge doses of A-I and A-II were tested. The experiments were terminated 60-90 min after administration of SQ 20881 l In three dogs responses to A-I and A-II were examined before and during infusion of P-113 ( 100 ,ug/kg per min). Infusion of P-l 13 into the inflow side of the perfusion pump (0.5 ml/min) was in progress for 5 min prior to commencing agonist challenges and was maintained until challenges were completed. Studies in the hindlimb, coronary, and hepatic (6) Collection of hindlimb venous blood during and for 2 min after injection of A-I (0.8 ,ug) into the perfusion line so that none of the injected agonist reached the systemic circulation did not alter the local response to A-I. Injection of A-I (n = 3) increased perfusion pressure to 128 =t 5 % of control when hindlimb venous blood was diverted from the dog, but systemic arterial pressure was not altered. When the injection was repeated while hindlimb venous blood was permitted to return to the dog (see METHODS), the same dose of A-I increased perfusion pressure to 126 & 6 % of control. A delayed increase in mean arterial pressure occurred (24 & 5 mm Hg) when the injected agonist was permitted to reach the systemic circulation. Injections of A-I or A-II into the perfusion system of 11 dogs caused dose-dependent increases in hindlimb perfusion pressure (Fig. 1 ) which were rapid in onset ( 10-l 5 set), attained maximal levels in about 20 set, and returned to control levels in an additional l-3 min (Fig. 2) . Injections of saline into the perfusion system usually produced a transient decrease in perfusion pressure. Similar decreases were seen with either A-I or A-II prior to the marked increase resulting from drug-induced vasoconstriction. These transient decreases in perfusion pressure were interpreted as local responses produced by the injection maneuver and were not studied further.
Although dose-response curves for A-I and A-II were similar in shape, the response to A-I was always smaller than the response to an equal weight of A-II. Generally, A-II was about 4 times as potent as A-I.
For each dose of A-I tested, the dose of A-II required to produce an equivalent increase in hindlimb perfusion pressure can be estimated from the dose-response curves for A-I and A-II (Fig. l) , Thus, 0.4 pg of A-I increased perfusion pressure to about 112 % of control, whereas only 0.1 pg of A-II caused the same response. If the response to A-I is ascribable to local enzymatic conversion to A-II, the results suggest that about 31 % of the injected A-I could be converted to angiotensin II. That is, the dose of A-II (0.1 pg) divided by the dose of A-I (0.4 pg) that produced the same increase in perfusion pressure (12 % increase), when multiplied by the factor 1. min ia) significantly attenuated hindlimb vasoconstriction caused by either A-I or A-II (Fig-4) , but did not alter responses to norepinephrine.
Prior to administration of P-l 13, norepinephrine (2 pg ia) increased hindlimb perfusion pressure to 130 rt 6 % of control (n = 3). After administration of P-113, norepinephrine increased perfusion pressure to 132 & 6 % of control. Blockade of responses produced with either A-I or A-II persisted for 30-60 min after the infusion of P-113 was terminated. It is possible that formation of A-II from injected A-I occurs in blood during the time required for transit from site of injection to site of action in the responsive vasculatures. This is not likely, since the angiotensin converting activity in dog blood is simply too low to permit extensive conversion of A-I to A-II in the time elapsed between injection of A-I into the pump-perfusion system and onset of either hindlimb or coronary vasoconstriction (24, 28 
